Lifeward (LFWD) announced the U.S. national launch of the ReWalk 7 Personal Exoskeleton, the next generation of its personal exoskeleton technology. The Company will now begin sales of ReWalk 7, which includes innovative new and enhanced features such as cloud connectivity and customizable walking speeds, to provide a more functional and personalized walking experience for individuals with spinal cord injury.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFWD:
- Lifeward Announces Termination of Chief Sales Officer
- Lifeward announces FDA clearance for ReWalk 7 exoskeleton
- Positive Outlook for Lifeward Driven by Strategic Partnerships and Market Expansion Initiatives
- Lifeward price target lowered to $4 from $4.50 at Lake Street
- Rewalk Robotics Earnings Call: Growth Amid Challenges